CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
Dietmar Trenk, PhD*,*,
Willibald Hochholzer, MD*,
Martin F. Fromm, MD ,
Ligia-Emilia Chialda, MD ,
Andreas Pahl, PhD ,
Christian M. Valina, MD*,
Christian Stratz, MD*,
Peter Schmiebusch, MD*,
Hans-Peter Bestehorn, MD*,
Heinz Joachim Büttner, MD* and
Franz-Josef Neumann, MD*
* Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nuremberg, Erlangen, Germany.
Manuscript received September 10, 2007;
revised manuscript received November 30, 2007,
accepted December 10, 2007.
* Reprint requests and correspondence: Dr. Dietmar Trenk, Herz-Zentrum Bad Krozingen, Suedring 15, D-79189 Bad Krozingen, Germany. (Email: dietmar.trenk{at}herzzentrum.de).
Objectives: We investigated whether the loss of function CYP2C19 681G>A *2 polymorphism is associated with high (>14%) residual platelet aggregation (RPA) on clopidogrel and whether high on-clopidogrel RPA impacts clinical outcome after elective coronary stent placement.
Background: The cytochrome P450 (CYP)–dependent conversion of clopidogrel to its active metabolite may contribute to the variability in antiplatelet effect of clopidogrel.
Methods: The study included 797 consecutive patients undergoing percutaneous coronary intervention, who were followed-up for 1 year. Adenosine-diphosphate–induced (5 µmol/l) RPA was assessed after a 600-mg loading dose and after the first 75-mg maintenance dose of clopidogrel before discharge. CYP2C19 genotype was analyzed by real-time polymerase chain reaction.
Results: Of the patients included, 552 (69.3%) were CYP2C19 wild-type homozygotes (*1/*1) and 245 (30.7%) carried at least one *2 allele. Residual platelet aggregation at baseline did not differ significantly between genotypes. On clopidogrel, RPA was significantly (p < 0.001) higher in *2 carriers than in wild-type homozygotes (23.0% [interquartile range (IQR) 8.0% to 38.0%] vs. 11.0% [IQR 3.0% to 28.0%] after loading; 11.0% [IQR 5.0% to 22.0%] vs. 7.0% [IQR 3.0% to 14.0%] at pre-discharge). Between *2 carriers and wild-type homozygotes, we found significant (p < 0.001) differences in the proportion of patients with RPA >14%, both after loading (62.4% vs. 43.4%) and at pre-discharge (41.3% vs. 22.5%). Residual platelet aggregation >14% at pre-discharge incurred a 3.0-fold increase (95% confidence interval 1.4 to 6.8; p = 0.004) in the 1-year incidence of death and myocardial infarction.
Conclusions: Patients carrying at least one CYP2C19*2 allele are more prone to high-on clopidogrel platelet reactivity, which is associated with poor clinical outcome after coronary stent placement (Effect of Clopidogrel Loading and Risk of PCI [EXCELSIOR]; NCT00457236
[ClinicalTrials.gov]
).
|
Abbreviations and Acronyms
| | ADP = adenosine diphosphate | | CI = confidence interval | | CYP = cytochrome P450 | | GP = glycoprotein | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | PCR = polymerase chain reaction | | RPA = residual platelet aggregation |
|
Related Articles
-
Clopidogrel Resistance: More Grist for the Mill
- John A. Cairns and John Eikelboom
J. Am. Coll. Cardiol. 2008 51: 1935-1937.
[Full Text]
[PDF]
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A31-A32.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
G. Montalescot, J.-S. Hulot, and J.-P. Collet
Stent thrombosis: who's guilty?
Eur. Heart J.,
November 2, 2009;
30(22):
2685 - 2688.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Hagihara, M. Kazui, A. Kurihara, M. Yoshiike, K. Honda, O. Okazaki, N. A. Farid, and T. Ikeda
A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel
Drug Metab. Dispos.,
November 1, 2009;
37(11):
2145 - 2152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Geisler, C. Zurn, R. Simonenko, M. Rapin, H. Kraibooj, A. Kilias, B. Bigalke, K. Stellos, M. Schwab, A. E. May, et al.
Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions
Eur. Heart J.,
October 6, 2009;
(2009)
ehp402v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Rudez, H. J. Bouman, J. W. van Werkum, F. W.G. Leebeek, A. Kruit, H. J.T. Ruven, J. M. ten Berg, M. P.M. de Maat, and C. M. Hackeng
Common Variation in the Platelet Receptor P2RY12 Gene Is Associated With Residual On-Clopidogrel Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary Interventions
Circ Cardiovasc Genet,
October 1, 2009;
2(5):
515 - 521.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Cuisset, C. Frere, J. Quilici, R. Poyet, B. Gaborit, L. Bali, O. Brissy, P.-E. Morange, M.-C. Alessi, and J.-L. Bonnet
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
J. Am. Coll. Cardiol.,
September 22, 2009;
54(13):
1149 - 1153.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Marin, R. Gonzalez-Conejero, P. Capranzano, T. A. Bass, V. Roldan, and D. J. Angiolillo
Pharmacogenetics in cardiovascular antithrombotic therapy.
J. Am. Coll. Cardiol.,
September 15, 2009;
54(12):
1041 - 1057.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-P. Collet and G. Montalescot
Review: Platelet Function Testing and Implications for Clinical Practice
Journal of Cardiovascular Pharmacology and Therapeutics,
September 1, 2009;
14(3):
157 - 169.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. R. Shuldiner, J. R. O'Connell, K. P. Bliden, A. Gandhi, K. Ryan, R. B. Horenstein, C. M. Damcott, R. Pakyz, U. S. Tantry, Q. Gibson, et al.
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
JAMA,
August 26, 2009;
302(8):
849 - 857.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Bhatt
Tailoring Antiplatelet Therapy Based on Pharmacogenomics: How Well Do the Data Fit?
JAMA,
August 26, 2009;
302(8):
896 - 897.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Verstuyft, T. Simon, and R. B. Kim
Personalized medicine and antiplatelet therapy: ready for prime time?
Eur. Heart J.,
August 2, 2009;
30(16):
1943 - 1963.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Varenhorst, S. James, D. Erlinge, J. T. Brandt, O. O. Braun, M. Man, A. Siegbahn, J. Walker, L. Wallentin, K. J. Winters, et al.
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
Eur. Heart J.,
July 2, 2009;
30(14):
1744 - 1752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. B Norgard, K. D Mathews, and G. C Wall
Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors
Ann. Pharmacother.,
July 1, 2009;
43(7):
1266 - 1274.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2080 - 2097.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Barker and H. V. Anderson
Acute coronary syndromes: don't bypass the clopidogrel.
J. Am. Coll. Cardiol.,
May 26, 2009;
53(21):
1973 - 1974.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Price
Bedside Evaluation of Thienopyridine Antiplatelet Therapy
Circulation,
May 19, 2009;
119(19):
2625 - 2632.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Mega, S. L. Close, S. D. Wiviott, L. Shen, R. D. Hockett, J. T. Brandt, J. R. Walker, E. M. Antman, W. L. Macias, E. Braunwald, et al.
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
Circulation,
May 19, 2009;
119(19):
2553 - 2560.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. F. Ford
Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?
J. Clin. Pharmacol.,
May 1, 2009;
49(5):
506 - 512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, K. Dorrler, T. Morath, A. Schomig, A. Kastrati, and N. von Beckerath
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Eur. Heart J.,
April 2, 2009;
30(8):
916 - 922.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Smyth, D. S. Woulfe, J. I. Weitz, C. Gachet, P. B. Conley, S. G. Goodman, M. T. Roe, A. Kuliopulos, D. J. Moliterno, P. A. French, et al.
G-Protein-Coupled Receptors as Signaling Targets for Antiplatelet Therapy
Arterioscler Thromb Vasc Biol,
April 1, 2009;
29(4):
449 - 457.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Ang and E. Mahmud
Reply
J. Am. Coll. Cardiol.,
March 10, 2009;
53(10):
901 - 901.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008.
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Freedman and E. M. Hylek
Clopidogrel, Genetics, and Drug Responsiveness
N. Engl. J. Med.,
January 22, 2009;
360(4):
411 - 413.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P. G. Steg, J. Ferrieres, N. Danchin, L. Becquemont, et al.
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
N. Engl. J. Med.,
January 22, 2009;
360(4):
363 - 375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Mega, S. L. Close, S. D. Wiviott, L. Shen, R. D. Hockett, J. T. Brandt, J. R. Walker, E. M. Antman, W. Macias, E. Braunwald, et al.
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
N. Engl. J. Med.,
January 22, 2009;
360(4):
354 - 362.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Gladding, M. Webster, I. Zeng, H. Farrell, J. Stewart, P. Ruygrok, J. Ormiston, S. El-Jack, G. Armstrong, P. Kay, et al.
The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response: An Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
620 - 627.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Kleiman
Searching for the Ceiling: New Reflections on the Disposition and Metabolism of Clopidogrel
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
628 - 630.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Bhatt, J. Scheiman, N. S. Abraham, E. M. Antman, F. K.L. Chan, C. D. Furberg, D. A. Johnson, K. W. Mahaffey, E. M. Quigley, R. A. Harrington, et al.
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
J. Am. Coll. Cardiol.,
October 28, 2008;
52(18):
1502 - 1517.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Writing Committee Members, D. L. Bhatt, J. Scheiman, N. S. Abraham, E. M. Antman, F. K.L. Chan, C. D. Furberg, D. A. Johnson, K. W. Mahaffey, and E. M. Quigley
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
Circulation,
October 28, 2008;
118(18):
1894 - 1909.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Cairns and J. Eikelboom
Clopidogrel Resistance: More Grist for the Mill
J. Am. Coll. Cardiol.,
May 20, 2008;
51(20):
1935 - 1937.
[Full Text]
[PDF]
|
 |
|
|